Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: A randomized, controlled trial (JUNCTURE)

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 6, 2015, Pages 1082-1090

  Paul, C ^a   Lacour, J P ^b   Tedremets, L ^c   Kreutzer, K ^d   Jazayeri, S ^e   Adams, S ^f   Guindon, C ^g   You, R ^h   Papavassilis, C ^g  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c Medicum Ltd   (Estonia)

^d OWL University   (Germany)

^e Alliance Dermatology and MOHS Center   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g NOVARTIS PHARMA AG   (Switzerland)

^h Beijing Novartis Pharma Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SECUKINUMAB; DERMATOLOGICAL AGENT; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; AUTOINJECTOR; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SELF INJECTION; SELF INJECTION ASSESSMENT QUESTIONNAIRE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DEVICES; DRUG SELF ADMINISTRATION; EQUIPMENT DESIGN; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; SELF CONCEPT; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; EQUIPMENT DESIGN; FEMALE; HEADACHE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-17; MALE; MIDDLE AGED; NASOPHARYNGITIS; PATIENT SATISFACTION; PRURITUS; PSORIASIS; SELF ADMINISTRATION; SELF EFFICACY; SEVERITY OF ILLNESS INDEX; SYRINGES; TREATMENT OUTCOME;

EID: 84929629144     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12751     Document Type: Article

References (23)

1. Martin DA, Towne JE, Kricorian G, et al,. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013; 133: 17-26.
2. Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW,. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 2010; 135: 108-117.
3. Ivanov S, Linden A,. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009; 30: 95-103.
4. Hueber W, Patel DD, Dryja T, et al,. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
5. Papp KA, Langley RG, Sigurgeirsson B, et al,. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412-421.
6. Rich P, Sigurgeirsson B, Thaci D, et al,. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402-411.
7. Langley RG, Elewski BE, Lebwohl M, et al,. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
8. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H,. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8.
9. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA,. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-374.
10. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R,. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-897.
11. Bewley A, Page B,. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011; 25 (Suppl 4): 9-14.
12. Pozzilli C, Schweikert B, Ecari U, Oentrich W, BetaPlus Study Group. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis-results of the BetaPlus observational cohort study. J Neurol Sci 2011; 307: 120-126.
13. Kivitz A, Cohen S, Dowd JE, et al,. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006; 28: 1619-1629.
14. Paul C, Stalder JF, Thaçi D, et al,. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 448-455.
15. Bayas A,. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 2013; 10: 285-287.
16. Lugaresi A,. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009; 6: 995-1002.
17. Humira (adalimumab) injection [package insert]. North Chicago, IL: AbbVie Inc. 2013. URL http://www.rxabbvie.com/pdf/humira.pdf. (last accessed: 23 May 2014).
18. Enbrel (etanercept) injection [package insert]. Thousand Oaks, CA: Immunex Corporation. 2013. URL http://pi.amgen.com/united
19. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C,. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2013; Dec 20. [Epub ahead of print]
20. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
21. Keininger D, Coteur G,. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes 2011; 9: 2.
22. Gaffen SL, Hernández-Santos N, Peterson AC,. IL-17 signaling in host defense against Candida albicans. Immunol Res 2011; 50: 181-187.
23. Krstic A, Mojsilovic S, Jovcic G, Bugarski D,. The potential of interleukin-17 to mediate hematopoietic response. Immunol Res 2012; 52: 34-41.